Glaxosmithkline Pharmaceuticals Ltd
NSE: GLAXO BSE: 500660
₹2594.40
(-2.78%)
Fri, 13 Feb 2026, 02:21 pm
Market Cap451.8B
PE Ratio43.05
Dividend1.57
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1924
- Incorporated as H.J. Foster & Co. Limited for distributing Glaxo baby food.
1926
- Became wholly-owned subsidiary of Joseph Nathan & Co.
1950
- Name changed to Glaxo Laboratories (I) Ltd.
1956
- Established vaccine manufacturing facilities.
1960
- Opened milk drying plant near Aligarh.
1961
- Commissioned fine chemicals plant at Thane.
1962
- Took over Indian branch of Allen & Hanburys Ltd.
1968
- Glaxo Group acquired BDH Group Ltd.
- Became public limited company; name changed to Glaxo Laboratories (India) Ltd.
- Diversified Aligarh factory with Glaxose-D and Casilan.
- Established R&D unit at Thane.
1970
- Acquired Vasant Vijay Mills premises at Worli.
- Completed new R&D unit at Thane.
1982
- Glaxo Group disinvested 28,00,000 equity shares.
1983
- Issued 56,00,000 equity shares at premium Rs. 5.
- Repaid preference capital.
1984
- Acquired Glindia Investments Ltd, Sesame Investments, Samgir Investments as subsidiaries.
1986
- Registered K G Gluco Biols Ltd as JV.
- Incorporated Vegepro Food & Feeds Ltd as JV.
1987
- Name changed to Glindia Limited.
- Launched Farex-Veg and Farex Egg.
- Received letters of intent for salbutamol and labetalol.
1988
- Launched Fortun antibiotic.
- Issued 20,00,000 14% redeemable debentures.
1989
- Name changed to Glaxo India Limited.
1990
- Launched Vitamilk, Minitmilk, Rozana.
- Issued commercial paper for Rs. 10 crore.
1991
- Issued commercial paper for Rs. 9.8 crore.
1992
- Received licences for ranitidine expansion and beclomethasone inhalers.
- Sold investment in Vegepro Foods & Feeds Ltd.
- Launched MINIT MILK, GLACTO I & II, FAREX RICE, AQUAVEETA.
1993
- Agreement with H.J. Heinz for family products disposal.
- Issued equity shares on rights and preferential basis to Glaxo Group to reach 51%.
- Received CRISIL P1+ rating.
1994
- Sold family products division to H.J. Heinz for Rs. 180 crore.
- Issued 1:1 bonus shares.
- Launched CETZINE, ZUCOX & RIZAP, BECORIDE.
1995
- Marketing tie-up with Grampian for veterinary products.
- Issued 1:1 bonus shares.
- Ankleshwar factory received Glaxo Wellcome award.
1996
- Formed specialised Onco, Dermo, and Rural teams.
- Thane factory received Glaxo Wellcome award.
1997
- Expanded Thane and Ankleshwar factories.
- Merged with Burroughs Wellcome, becoming largest pharma with 7.2% market share.
1998
- Issued 20,00,000 14% redeemable debentures.
- Marketing tie-up between Qualigens and Oxoid for culture media.
1999
- Agreement with Ranbaxy for co-marketing cephalexin.
- Acquired 5 veterinary brands from ICI India.
2000
- Glaxo Group held 51% equity.
- Tied up with Merial for poultry vaccines.
- Launched Hepitec for Hepatitis B and Seretide for asthma.
- Sold Anovate and Livogen brands.
- Parent companies Glaxo Wellcome and SmithKline merged to GlaxoSmithKline plc.
2001
- Marketing alliance with Allergan for Catalin.
- Merged with SmithKline Beecham Pharmaceuticals India to become GlaxoSmithKline Pharmaceuticals Ltd.
- High Courts approved amalgamation.
2002
- Approved scheme for demerger of Meghdoot and amalgamation of Croydon.
- Shut down Biddle Sawyer subsidiary.
- Sold Ankleshwar API facility to Glenmark for Rs. 14 crore.
- Appointed S. Kalyanasundaram as MD.
- Bombay HC approved scheme of arrangement with subsidiaries.
2003
- Filed SLP in Supreme Court on medicine pricing.
- Sold Bangalore office for Rs. 231 million.
- Delhi HC restrained KPS from using marks similar to Ostocalcium.
- Sued Dr. Reddy's for patent infringement.
- Entered drug discovery collaboration with Ranbaxy.
2004
- Appointed Dr. Ashoke Banerjee as Executive Director.
- Sold Worli plot for Rs. 107.6 crore.
- Launched Phase III study of cervical cancer vaccine.
- Augmentin became No. 1 pharmaceutical brand.
- Launched Priorix MMR vaccine.
- Received Multi Cultural Diversity Award for Famili Vaccines programme.
2005
- Laid foundation stone for vaccines plant at Nashik.
- Launched oral contraceptives Elogen and Zerogen.
- Entered diabetes segment with Windia (rosiglitazone) and Windamet.
2006
- Augmentin grew to Rs. 100 crore brand.
- In-licensing alliance with Eisai; launched Parit (rabeprazole).
- Divested Agrivet Farm Care business.
2007
- Launched Carzec (carvedilol) and Zemetril (cefprozil).
- Divested Qualigens Fine Chemicals business.
- Launched Arixtra (fondaparinux) for DVT and ACS.
2008
- Pact with Astellas for exclusive rights to Mycamine.
- Co-promotion agreement with Daiichi Sankyo for Olmesartan products.
- Launched Boostrix, Infanrix, Rotarix vaccines.
- Launched Tykerb for advanced breast cancer.
- Launched Benitec and Benitec-H antihypertensives.
2009
- Deal with Dr. Reddy's to manufacture over 100 products.
- Launched Cervarix HPV vaccine.
- Launched Dermocalm for dry itchy skin.
- Commenced Albendazole production in Nashik for Lymphatic Filariasis.
2010
- Net sales up 14%, PBT before exceptional items up 14%.
- CEO Andrew Witty dedicated Albendazole facility in Nashik to WHO Lymphatic Filariasis programme.
2011
- Launched Revolade (Eltrombopag) for chronic ITP.
- Launched Votrient (Pazopanib) for advanced renal cell carcinoma.
2012
- Introduced Metered Dose Inhaler with dose counter.
- Observed World Asthma Day.
- Conducted survey revealing women prioritising work over cervical cancer health.
2013
- Recommended dividend of Rs. 50 per equity share.
2014
- Recommended dividend of Rs. 50 per equity share.
2015
- Acquired Novartis vaccines business and divested marketed oncology portfolio to Novartis India.
2016
- Launched school sanitation project at Nashik, Maharashtra.
2017
- Q3 net sales declined 6% with underlying volume growth of 8%.
2018
- Announced bonus share issue in 1:1 ratio.
- Acquired Tesaro for $5.1 billion.
- Combined consumer health businesses with Pfizer in JV.
2019
- Won Brand of the Year award in acute category at 6th AWACS Awards.
- Won Best Sales and Operations Planning Practice in Pharma award.
- Recognised as Best Workplaces for Women by Great Places to Work India.
2020
- Recognised as one of 100 Best Companies for Women in India by Working Mother and AVTAR.
- Conferred Fair Business Practices award (2019-20) by Council for Fair Business Practices.
- Recognised as Silver employer under India Workplace Equality Index.
2021
- Recognised as one of India's Best Workplaces in Health & Wellness by Great Place to Work.
- Conferred CNBC TV18 India Risk Management Award in Pharma sector.
2022
- Launched once-daily single inhaler-triple therapy for COPD patients.
- Teamed up with MS Dhoni for 6-in-1 vaccination awareness campaign.
2024
- Reported strong double-digit growth and improved profitability for the quarter.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800